GenEdit utilizes the NanoGalaxy® delivery platform to enhance the safe and efficient delivery of CRISPR-Cas9 gene editing therapies for genetic diseases. This technology addresses the challenge of limited access to effective genetic medicines, enabling broader patient treatment options.
Funding
$24M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current CRISPR-Cas9 gene editing therapies face challenges in safe and efficient delivery, limiting their accessibility and effectiveness for treating a wide range of genetic diseases. The lack of targeted delivery mechanisms hinders the ability of these therapies to reach the intended cells and tissues, reducing their therapeutic potential.
Solution
GenEdit is developing the NanoGalaxy® delivery platform to improve the delivery of CRISPR-Cas9 gene editing therapies. This platform aims to enhance the safety, specificity, and efficiency of gene editing by enabling targeted delivery of therapeutic payloads to specific cells and tissues within the body. By overcoming delivery limitations, NanoGalaxy® seeks to expand the range of treatable diseases and improve patient outcomes. The platform is designed to facilitate the development of innovative genetic medicines that can effectively edit out disease and rewrite patient health.
Target Audience
The primary target audience includes researchers and pharmaceutical companies developing CRISPR-Cas9 based gene editing therapies for genetic diseases.
Features
- Targeted delivery of CRISPR-Cas9 components to specific cells and tissues
- Enhanced safety profile compared to traditional delivery methods
- Improved efficiency of gene editing within target cells
- Versatile platform applicable to a wide range of genetic diseases